Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma
Nadeem, Omar, Magidson, Sophie, Midha, Shonali, O'Donnell, Elizabeth K., Hartley-Brown, Monique A, Sperling, Adam S., Redd, Robert A., Marto, Marjorie, Davie, Christine, Ricciardi, Caroline, Choden, Dechen, Strutevant, Ashlee, Alberti, Jillian, Mo, Clifton C., Laubach, Jacob, Richardson, Paul G., Anderson, Kenneth C., Munshi, Nikhil C, Trippa, Lorenzo, Ghobrial, Irene M.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Nadeem, Omar, Magidson, Sophie, Redd, Robert A., Laubach, Jacob, Mo, Clifton C., O'Donnell, Elizabeth K., Sperling, Adam S., Hartley-Brown, Monique A, Midha, Shonali, Marto, Marjorie, Davie, Christine, Ricciardi, Caroline, Choden, Dechen, Strutevant, Ashlee, Alberti, Jillian, Trippa, Lorenzo, Munshi, Nikhil C, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
P-099 Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
Nadeem, Omar, Redd, Robert, Mo, Clifton, Laubach, Jacob, Richardson, Paul G., Prescott, Julia, Marto, Marjorie, Davie, Christine, Ricciardi, Caroline, Murphy, Elizabeth, Bertoni, Meredith, Choden, Dechen, Magidson, Sophie, Sheehan, Brian, Shrestha, Hira, Sperling, Adam S., O'Donnell, Elizabeth K., Ghobrial, Irene M.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article